Electromagnetic Navigation Bronchoscopy for Peripheral Pulmonary Lesions: One-Year Results of the Prospective, Multicenter NAVIGATE Study

Erik Folch(Massachusetts General Hospital), Michael A. Pritchett(FirstHealth of the Carolinas), Michael Nead(University of Rochester Medical Center), Mark Bowling(East Carolina University), Septimiu Murgu(University of Chicago), William Krimsky(Pulmonary and Critical Care Associates), Boris A. Murillo(Providence College), Gregory P. LeMense(Alcoa (United States)), Douglas J. Minnich(Princeton Baptist Medical Center), Sandeep Bansal(Penn Highlands Healthcare), Blesilda Q. Ellis(Pulmonary Associates), Amit Mahajan(Inova Health System), Thomas R. Gildea(Cleveland Clinic), Rabih Bechara(Cancer Treatment Centers of America), Eric Sztejman(Virtua Health), Javier Flandes(Hospital Universitario Fundación Jiménez Díaz), Otis B. Rickman(Vanderbilt University Medical Center), Sadia Benzaquen(University Physicians), D. Kyle Hogarth(University of Chicago), Philip A. Linden(University Hospitals of Cleveland), Momen M. Wahidi(Duke Medical Center), Jennifer Mattingley(Gundersen Health System), Kristin L. Hood(Medtronic (United States)), Haiying Lin(Medtronic (United States)), Jennifer J. Wolvers(Medtronic (United States)), Sandeep J. Khandhar(Inova Health System), Carlos Anciano, Alejandro Aragaki, Douglas A. Arenberg(University of Alabama at Birmingham), Omar Awais, Ricardo Balestra, Sandeep Bansal(Penn Highlands Healthcare), Emanuela Barisione, Rabih Bechara(Morehouse School of Medicine), Sadia Benzaquen(University Physicians), Michela Bezzi, K Bhadra, Julio Bird, Alessandro Blanco, Mark Bowling(East Carolina University), Robert J. Cerfolio, Merete Bechmann Christensen, Joseph Cicenia, Antony Courey, John D. Doty, Kevin L. Eggleston, Blesilda Q. Ellis(Pulmonary Associates), I. Gallo Fernández, Javier Flandes(Hospital Universitario Fundación Jiménez Díaz), Erik Folch(Massachusetts General Hospital), Alexandre M Furman, George David Gass, Thomas R. Gildea(Cleveland Clinic), Anil Gogineni, Musija Fikreta Grabcanovic, John David Hinze, D. Kyle Hogarth(University of Chicago), Raj Karunakara, Jordan Kazakov, Sandeep J. Khandhar(Inova Health System), Sandhya Khurana, William Krimsky(Pulmonary and Critical Care Associates), Ganesh Krishna, Roman Krol, Roland Kropfmüller, Bernd Lamprecht, Kelvin Lau, Andrew Lee, Gregory P. LeMense(Alcoa (United States)), Philip A. Linden(University Hospitals of Cleveland), Peter Lutz, Amit Mahajan(Inova Health System), Kamran Mahmood, Fabien Maldonado, R. Martos Martínez, Jennifer Mattingley(Medtronic (United States)), Douglas J. Minnich(University of Alabama at Birmingham), Septimiu Murgu(University of Chicago), Boris A. Murillo(Providence College), Katie S. Nason, Michael Nead(University of Rochester Medical Center), Christopher Parks, Kenneth Perret, Peter Porsch, Michael A. Pritchett(FirstHealth of the Carolinas), Otis B. Rickman(Vanderbilt University Medical Center), M. Del Rosario, Mario Salio, Saiyad Sarkar, Andrew Seevaratnam, Sonali Sethi, Jaspal Singh, Michael Studnicka(University of Rochester Medical Center), Eric Sztejman(Virtua Health), Tamejiro Takubo, C.V. Teba, Christopher W. Towe, Marco Trigiani, JeanRichel Vergnon, Niels‐Erik Viby, Momen M. Wahidi(Duke Medical Center), E. Andrew Waller, Benjamin Wei, Dragos Zanchi, Michael Zgoda(University of Rochester Medical Center)
Journal of Thoracic Oncology
November 23, 2018
Cited by 404Open Access
Full Text

Abstract

INTRODUCTION: Electromagnetic navigation bronchoscopy (ENB) is a minimally invasive technology that guides endoscopic tools to pulmonary lesions. ENB has been evaluated primarily in small, single-center studies; thus, the diagnostic yield in a generalizable setting is unknown. METHODS: NAVIGATE is a prospective, multicenter, cohort study that evaluated ENB using the superDimension navigation system (Medtronic, Minneapolis, Minnesota). In this United States cohort analysis, 1215 consecutive subjects were enrolled at 29 academic and community sites from April 2015 to August 2016. RESULTS: The median lesion size was 20.0 mm. Fluoroscopy was used in 91% of cases (lesions visible in 60%) and radial endobronchial ultrasound in 57%. The median ENB planning time was 5 minutes; the ENB-specific procedure time was 25 minutes. Among 1157 subjects undergoing ENB-guided biopsy, 94% (1092 of 1157) had navigation completed and tissue obtained. Follow-up was completed in 99% of subjects at 1 month and 80% at 12 months. The 12-month diagnostic yield was 73%. Pathology results of the ENB-aided tissue samples showed malignancy in 44% (484 of 1092). Sensitivity, specificity, positive predictive value, and negative predictive value for malignancy were 69%, 100%, 100%, and 56%, respectively. ENB-related Common Terminology Criteria for Adverse Events grade 2 or higher pneumothoraces (requiring admission or chest tube placement) occurred in 2.9%. The ENB-related Common Terminology Criteria for Adverse Events grade 2 or higher bronchopulmonary hemorrhage and grade 4 or higher respiratory failure rates were 1.5% and 0.7%, respectively. CONCLUSIONS: NAVIGATE shows that an ENB-aided diagnosis can be obtained in approximately three-quarters of evaluable patients across a generalizable cohort based on prospective 12-month follow-up in a pragmatic setting with a low procedural complication rate.


Related Papers

No related papers found

Powered by citation graph analysis